

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sinco Pharmaceuticals Holdings Limited**

### **兴科蓉医药控股有限公司**

*(Incorporated under the laws of the Cayman Islands with limited liability)*

**(Stock Code: 6833)**

## **CHANGE OF COMPANY SECRETARY CHANGE OF AUTHORISED REPRESENTATIVE CHANGE OF PROCESS AGENT AND WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

### **CHANGE OF COMPANY SECRETARY, AUTHORISED REPRESENTATIVE AND PROCESS AGENT**

The board (the “**Board**”) of directors (the “**Director(s)**”) of Sinco Pharmaceuticals Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Ms. Ko Wing Yu (“**Ms. Ko**”) has tendered her resignation due to change of job assignment as (i) the company secretary of the Company; (ii) the authorised representative of the Company under Rule 3.05 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) (the “**Authorised Representative**”); and (iii) the authorised representative of the Company for the purposes of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the “**Process Agent**”) with effect from 25 October 2019.

Ms. Ko confirmed that she has no disagreement with the Board and there are no matters in relation to her resignation that needs to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company. The Company would like to express its gratitude to Ms. Ko for her valuable contributions to the Company during her term of office.

The Board announces that Ms. Peng Yunlu (“**Ms. Peng**”) and Ms. Li Ching Yi (“**Ms. Li**”) have been appointed as joint company secretaries of the Company with effect from 25 October 2019. The Board also announces that Ms. Li has been appointed as the Authorised Representative and Ms. Peng has been appointed as the Process Agent, both effective from 25 October 2019.

Ms. Peng, aged 28, is currently the Deputy Director and the Secretary to the President in the President Office of the Company. Ms. Peng is primarily responsible for coordinating the meetings of the Board and the shareholders, handling corporate disclosure pursuant to the Listing Rules as well as attending to corporate governance affairs. Ms. Peng joined the Group and has been working for Sichuan Sinco Pharmaceutical Co., Ltd (“**Sichuan Sinco**”) since 2013. She has held important positions in Quality Management Department, Purchasing Department, Capital Department and Accounting Department in Sichuan Sinco during the period. Ms. Peng holds a master degree in International Business from University of Birmingham.

Ms. Li is a manager of Trident Corporate Services (Asia) Limited, a global professional services firm. Ms. Li has over 8 years of experience in the company secretarial field and has been providing professional corporate secretarial and compliance services to listed companies. Ms. Li is an associate member of the Hong Kong Institute of Chartered Secretaries and the Institute of Chartered Secretaries and Administrators in the United Kingdom.

### **WAIVER FROM STRICT COMPLIANCE WITH RULES 3.28 AND 8.17 OF THE LISTING RULES**

Pursuant to Rule 8.17 of the Listing Rules, a listed issuer must appoint a company secretary who meets the requirements under Rule 3.28 of the Listing Rules. Rule 3.28 of the Listing Rules provides that a listed issuer must appoint as its company secretary an individual who, in the opinion of the Stock Exchange, is capable of discharging the functions of company secretary of the listed issuer by virtue of his/her academic or professional qualifications or relevant experience.

As at the date of this announcement, Ms. Peng does not possess the qualifications of company secretary as required under Rules 3.28 and 8.17 of the Listing Rules. However, she has knowledge and experience in corporate administrative matters and is familiar with the business and operations of the Group. As such, the Company has applied to the Stock Exchange for, and the Stock Exchange has granted, a waiver from strict compliance with the requirements under Rules 3.28 and 8.17 of the Listing Rules for a period of three years from the date of Ms. Peng’s appointment as a joint company secretary of the Company (the “**Waiver Period**”) on the grounds that the Company will engage Ms. Li, the other joint company secretary of the Company who possesses the relevant professional qualifications of company secretary required under Rules 3.28 and 8.17 of the Listing Rules, to provide assistance and guidance to Ms. Peng in discharging her duties as one of the joint company secretaries of the Company.

The waiver is granted on the conditions that (i) Ms. Peng will be assisted by Ms. Li during the Waiver Period; (ii) the Company shall notify the Stock Exchange at the end of the Waiver Period for the Stock Exchange to re-visit the situation. The Stock Exchange expects that, after the end of the Waiver Period, the Company will be able to demonstrate that Ms. Peng can satisfy Rule 3.28 of the Listing Rules, after having the benefit of Ms. Li’s assistance such that a further waiver will not be necessary; and (iii) the Company will announce the details of the waiver, including its reasons and conditions. The waiver applies to this case only and will be revoked immediately if and when Ms. Li ceases to be a joint company secretary of the Company.

The Board would like to extend its warm welcome to Ms. Peng and Ms. Li for taking up the appointment.

By Order of the Board  
**Sinco Pharmaceuticals Holdings Limited**  
**Huang Xiangbin**  
*Chairman and Executive Director*

Hong Kong, 25 October 2019

*As at the date of this announcement, the executive directors of the Company are Mr. Huang Xiangbin and Ms. Zhang Zhijie; and the independent non-executive directors of the Company are Mr. Lau Ying Kit, Mr. Wang Qing and Mr. Liu Wenfang.*